|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:appointed_by
|
oral route
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:clinical_trial
|
gptkb:healthcare_organization
gptkb:FDA
|
|
gptkbp:developed_by
|
gptkb:Loxo_Oncology
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Vitrakvi
|
|
gptkbp:includes
|
treatment guidelines
|
|
gptkbp:is_available_in
|
gptkb:various_countries
|
|
gptkbp:is_committed_to
|
precision medicine
|
|
gptkbp:is_evaluated_by
|
clinical trials
|
|
gptkbp:is_monitored_by
|
adverse effects
|
|
gptkbp:is_noted_for
|
adult and pediatric patients
|
|
gptkbp:is_supported_by
|
clinical evidence
|
|
gptkbp:is_used_for
|
treating cancer
|
|
gptkbp:is_used_in
|
solid tumors
|
|
gptkbp:key
|
Bayer's growth strategy
|
|
gptkbp:manufacturer
|
oncology pipeline
|
|
gptkbp:marketed_as
|
the brand name Vitrakvi
|
|
gptkbp:marketing_strategy
|
expand oncology offerings
|
|
gptkbp:pharmacokinetics
|
targeted therapies
NTRK proteins
|
|
gptkbp:significance
|
Bayer's drug lineup
|
|
gptkbp:targets
|
gptkb:NTRK_gene_fusions
tumors with NTRK gene fusions
|
|
gptkbp:treatment
|
cancer patients
specific genetic mutations
cancer patients with NTRK fusions
patients with NTRK fusions
|
|
gptkbp:bfsParent
|
gptkb:Loxo_Oncology
|
|
gptkbp:bfsLayer
|
4
|